These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 33527151

  • 1. Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry.
    Taylor VJ, Barnes PJ, Godwin SC, Bethune GC.
    Virchows Arch; 2021 Jul; 479(1):23-31. PubMed ID: 33527151
    [Abstract] [Full Text] [Related]

  • 2. HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern.
    Perron M, Wen HY, Hanna MG, Brogi E, Ross DS.
    Arch Pathol Lab Med; 2021 Aug 01; 145(8):979-987. PubMed ID: 33212478
    [Abstract] [Full Text] [Related]

  • 3. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC, Pettit AS, Veldhuijzen van Zanten D, Barnes PJ.
    Histopathology; 2017 May 01; 70(6):966-974. PubMed ID: 28032917
    [Abstract] [Full Text] [Related]

  • 4. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, Ikpatt OF, Gomez C, Zhao W, Reis IM.
    Breast Cancer Res Treat; 2016 Feb 01; 155(3):457-62. PubMed ID: 26895325
    [Abstract] [Full Text] [Related]

  • 5. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
    Geiersbach KB, Sill DR, Meyer RG, Yuhas JA, Sukov WR, Mounajjed T, Carter JM, Jenkins RB, Chen B.
    Arch Pathol Lab Med; 2021 Jul 01; 145(7):883-886. PubMed ID: 33112955
    [Abstract] [Full Text] [Related]

  • 6. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY.
    Hum Pathol; 2020 Apr 01; 98():10-21. PubMed ID: 32027910
    [Abstract] [Full Text] [Related]

  • 7. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS, Bowman AS, Zehir A, Razavi P, Brogi E, Ladanyi M, Arcila ME, Wen HY, Ross DS.
    Histopathology; 2021 Mar 01; 78(4):498-507. PubMed ID: 32841416
    [Abstract] [Full Text] [Related]

  • 8. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH, Wang K, Lin DY, Xu J, Chen J, Long XY, Ge Y, Luo XL, Zhang KP, Liu YH, Xu FP.
    Breast Cancer Res Treat; 2019 May 01; 175(1):51-57. PubMed ID: 30712197
    [Abstract] [Full Text] [Related]

  • 9. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH, Lim AS, Thike AA, Tien SL, Tan PH.
    Arch Pathol Lab Med; 2016 Feb 01; 140(2):140-7. PubMed ID: 26910218
    [Abstract] [Full Text] [Related]

  • 10. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K, Tantravahi U, Lomme MM, Pasquariello T, Steinhoff M, Sung CJ.
    Breast Cancer Res Treat; 2016 Jun 01; 157(3):405-11. PubMed ID: 27180259
    [Abstract] [Full Text] [Related]

  • 11. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L, Yuan P, Zhang J, Ling Y, Li W, Zhao B, Ying J, Xuan L.
    Breast Cancer Res Treat; 2017 Nov 01; 166(1):77-84. PubMed ID: 28712009
    [Abstract] [Full Text] [Related]

  • 12. Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
    Xu FP, Wang K, Xu J, Chen J, Zhang YF, Wu HM, Zhang MH, Long XX, Luo XL, Zhang KP, Lin DY, Liu YH.
    Breast Cancer Res Treat; 2017 Dec 01; 166(3):757-764. PubMed ID: 28861637
    [Abstract] [Full Text] [Related]

  • 13. Histologic analysis according to HER2 gene status in HER2 2 + invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations.
    Hwang HW, Hong SA, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Cho SY, Cho EY.
    Virchows Arch; 2022 Apr 01; 480(4):749-758. PubMed ID: 35138452
    [Abstract] [Full Text] [Related]

  • 14. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number ≥4.0 and <6.0.
    Hoda RS, Brogi E, Xu J, Ventura K, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY.
    Arch Pathol Lab Med; 2020 May 01; 144(5):597-601. PubMed ID: 31647316
    [Abstract] [Full Text] [Related]

  • 15. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
    Farra C, Fedda F, Tfayli A, Tawil A, Zaatari G, Ashkar H, Issa G, Boulos F.
    Clin Breast Cancer; 2019 Oct 01; 19(5):340-344. PubMed ID: 31213407
    [Abstract] [Full Text] [Related]

  • 16. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
    Crespo J, Sun H, Wu J, Ding QQ, Tang G, Robinson MK, Chen H, Sahin AA, Lim B.
    PLoS One; 2020 Oct 01; 15(11):e0241775. PubMed ID: 33180796
    [Abstract] [Full Text] [Related]

  • 17. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
    Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, Barr K, Deavers MT.
    Arch Pathol Lab Med; 2009 May 01; 133(5):775-80. PubMed ID: 19415952
    [Abstract] [Full Text] [Related]

  • 18. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE, Marotti JD, Memoli VA, Wells WA, Tafe LJ.
    Am J Clin Pathol; 2015 Aug 01; 144(2):247-52. PubMed ID: 26185309
    [Abstract] [Full Text] [Related]

  • 19. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
    Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ.
    JAMA Oncol; 2019 Mar 01; 5(3):366-375. PubMed ID: 30520947
    [Abstract] [Full Text] [Related]

  • 20. The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases.
    Zhang X, Bleiweiss I, Jaffer S, Nayak A.
    Clin Breast Cancer; 2017 Oct 01; 17(6):486-492. PubMed ID: 28433541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.